FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
about
Emerging therapies for breast cancerCyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.CDK4/6 inhibitors sensitize Rb-positive sarcoma cells to Wee1 kinase inhibition through reversible cell cycle arrest.Modeling and Targeting MYC Genes in Childhood Brain Tumors.Understanding cell cycle and cell death regulation provides novel weapons against human diseases.CDK4/6 Inhibition in Breast Cancer: Mechanisms of Response and Treatment Failure.Cdk6 contributes to cytoskeletal stability in erythroid cells.Combined CDK4/6 and mTOR Inhibition Is Synergistic against Glioblastoma via Multiple Mechanisms.Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targets.A hypothesis-driven approach identifies CDK4 and CDK6 inhibitors as candidate drugs for treatments of adrenocortical carcinomas.Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response.Strategies and Progress of Endocrine Therapy for Patients with Metastatic Breast Cancer.Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer.Dual cyclin-dependent kinase 4/6 inhibition by PD-0332991 induces apoptosis and senescence in oesophageal squamous cell carcinoma cells.Gain of 12p encompassing CCND2 is associated with gemistocytic histology in IDH mutant astrocytomas.Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer.Complete Response to Single-agent Palbociclib in Metastatic Breast Cancer: A Case Report.Cell Cycle Regulation in Treatment of Breast Cancer.The Dawning of Translational Breast Cancer: From Bench to Bedside.Circulating tumor DNA analyses reveal novel resistance mechanisms to CDK inhibition in metastatic breast cancer.Inhibition of cyclin-dependent kinase 4 as a potential therapeutic strategy for treatment of synovial sarcoma.Combined c-Met/Trk inhibition overcomes resistance to CDK4/6 inhibitors in Glioblastoma.PALINA: A phase II safety study of palbociclib in combination with letrozole or fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancer.Novel treatment strategies for patients with HER2-positive breast cancer who do not benefit from current targeted therapy drugsBreast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis
P2860
Q33617949-9936C822-8DDE-4352-AA62-58EBEA060BB0Q38662999-DD2DAA52-136D-46C6-9644-B5DFC1724DCAQ38723383-8FDF311C-7C91-425D-912B-6363EDB46E72Q39195507-E902C676-A0DE-4E9D-BF6B-B423C1FE5F25Q39218376-DDE57DF7-A2A1-41C8-B648-CD68FBD03A5EQ39289608-8FFC5B69-6865-44DD-B046-E6C7271B0BACQ41949980-BDF403C6-DBFB-4A82-A0F6-D6D669EECE01Q45065453-34D47668-53CF-4822-96D6-CDCB6F6D03D5Q47144472-2049E63C-4501-4E80-ADC5-8FBF77349A12Q47239499-78DB54DC-09CC-4F92-A48C-683AB587F2E0Q47321016-128A3FF2-8162-4B3C-A0DD-7FF13AEEED82Q47561979-D31A2DC5-69D6-4728-9CFD-7E80529208CFQ48230033-D790E053-EC14-4CCB-B3AA-9D22DB7C046CQ48231208-5FF59FC8-7B51-4F97-B122-D4E7FDD7254FQ48387987-67B9DABD-0848-4EEE-9AA8-13FEE913B3E0Q48512373-92010BA2-8C7D-4324-9A1D-476892654228Q49341306-9096A4F5-EC45-4292-BE3E-6800C197B0D7Q49544319-04B3B799-3293-46C2-A055-2E0D9860A838Q49544424-71F44771-ACE6-4008-8510-156A8B7E43F7Q49916796-AB853A0A-E264-40D0-B44C-551F58773499Q52579552-D6BAC4B3-02E8-4AFC-9106-CC9460DF75FCQ54977810-5945ADEC-93DB-480F-B249-FB107968319FQ55716886-4FBF7A09-04C3-4879-B57D-D74CE6E8F270Q57106864-7C1331F3-624B-4241-9CFE-1D9D06DF9FEEQ57112840-89A8F7C4-593C-485E-BF42-9C5D8F3D9830
P2860
FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
description
2016 nî lūn-bûn
@nan
2016 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
FDA Approval of Palbociclib in ...... tive Metastatic Breast Cancer.
@ast
FDA Approval of Palbociclib in ...... tive Metastatic Breast Cancer.
@en
type
label
FDA Approval of Palbociclib in ...... tive Metastatic Breast Cancer.
@ast
FDA Approval of Palbociclib in ...... tive Metastatic Breast Cancer.
@en
prefLabel
FDA Approval of Palbociclib in ...... tive Metastatic Breast Cancer.
@ast
FDA Approval of Palbociclib in ...... tive Metastatic Breast Cancer.
@en
P2093
P1476
FDA Approval of Palbociclib in ...... tive Metastatic Breast Cancer.
@en
P2093
Amanda J Walker
Amy E McKee
Amy Tilley
Erik Bloomquist
Geoffrey Kim
Jeanne Fourie Zirkelbach
Laleh Amiri-Kordestani
Paul G Kluetz
Rajeshwari Sridhara
P304
P356
10.1158/1078-0432.CCR-16-0493
P407
P577
2016-07-12T00:00:00Z